CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly ...

Eli Lilly has struck a $2.4 billion deal to buy Dice Therapeutics and its drug discovery and development platform for oral, small molecule therapies for immunological diseases. The big pharma is ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Dec 5 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year ...

Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its blockbuster diabetes and weight-loss drugs. The latest investment ...

or cardiovascular disease. The most commonly reported side effects among those taking both Zepbound and Wegovy were mild to moderate gastrointestinal symptoms, Lilly said. The drugmaker plans to ...

CORE Kidney, a patient support and advocacy group that helps patients with kidney disease navigate their complex journey, today announced its collaboration with Boehringer Ingelheim and Eli Lilly ...

There is no Morningstar’s Analysis data available.

LONDON — The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the greatest need as the country tries to adapt to new ways of ...